Navigation Links
Genzyme Announces Successful Completion of Study Investigating,Sevelamer Carbonate in Patients With Chronic Kidney Disease

CAMBRIDGE, Mass., April 16, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that a recently completed study of Renvela(TM) (sevelamer carbonate) achieved its primary endpoint, demonstrating a statistically significant reduction in serum phosphorus for hyperphosphatemic patients with chronic kidney disease who are not on dialysis.

Patients treated with Renvela also achieved a significant reduction in calcium-phosphorus product and in LDL cholesterol. The drug was well tolerated with a safety profile consistent with the clinical experience of patients on dialysis using Renagel(R) (sevelamer hydrochloride). The multi-center, single arm, open-label trial involved 49 patients at multiple study sites throughout Europe and Australia.

Full data will be presented at a future medical conference.

Renvela is a buffered form of Renagel, the most-prescribed phosphate binder in the United States. Like Renagel, Renvela is a calcium-free, metal- free, non-absorbed phosphate binder and will initially be available as 800mg tablets once approved.

The results announced today represent one portion of a comprehensive clinical program for sevelamer carbonate. Data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented last week at the spring clinical meeting of the National Kidney Foundation. In addition, enrollment is complete in two studies comparing a powder form of sevelamer carbonate to Renagel tablets dosed three times per day, including one study in which the powder form is dosed three times per day, and one in which it is dosed once per day.

A New Drug Application for Renvela is currently under review by the US Food and Drug Administration for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

About Renagel

Renagel controls serum phosphorus in patients with CKD on hemodialysis. Controlling serum ph
'"/>




Page: 1 2 3

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/30/2014)... -- Hospira, Inc. (NYSE: HSP ), the ... technologies, today reported results for the second quarter ... quarter were $1.1 billion and adjusted* diluted earnings ... items as described later in this press release ... Accepted Accounting Principles (GAAP) basis, second-quarter 2014 diluted ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... held biotech company that designs and develops novel ... management of cancer, announced today the completion of ... The financing included new investors RusnanoMedInvest (RMI) and ... Fund, and Pfizer Venture Investments, as well as ...
(Date:7/30/2014)... 30. Juli 2014 Die Apex ... Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, gibt ... München in Deutschland anfechten werden. Dieses hat ... ein Patent von ResMed verletze. Apex weist ... Ländern gegen verschiedene Patente von ResMed Anfechtungen ...
Breaking Medicine Technology:Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Sept. 23 Surefil, a contract manufacturer of liquid-fill ... medical industries, and energy drinks, emerged from Chapter 11 ... The company was able to attract ABACO Partners, LLC ... Executive Officer of Universal Forest Products, Bill Currie, to ...
... Netherlands, Sept. 23 DuPont (NYSE: DD ... form a joint venture to develop, manufacture and commercialize ... The joint venture will be named Actamax Surgical Materials ... will each share a 50 percent interest. The ...
Cached Medicine Technology:Surefil Emerges from Chapter 11 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 3DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 4
(Date:7/30/2014)... elderly American adults is being financially exploited often ... crisis especially affects poor and black people. It merits ... citizen who cares about the dignity and well-being of ... Medical College in the US. She led one of ... findings of which appear in the Journal of ...
(Date:7/30/2014)... hospital in Ireland has shown than many of them did ... the risk of entrapment. The report, published online in the ... for careful selection of patients for whom bedrails are to ... maintenance of hospital bed systems. , Bedrails are commonly used ... although the risk for any individual is extremely low, people ...
(Date:7/30/2014)... The report entitled “Global Pulse Oximetry Market: Trends ... dynamics and changing trends in the global pulse oximetry ... sizing of the global pulse oximetry market and also ... same. It further captures the global market share based ... Further, the report discusses the domestic market of United ...
(Date:7/30/2014)... Los Angeles cosmetic dentist , ... that can help patients create their dream smiles at ... gums form the foundation of smile confidence, but cosmetic ... misshapen teeth or stains may not interfere with dental ... The right cosmetic treatments can eliminate chips, erase stains ...
(Date:7/30/2014)... July 30, 2014 Building ENT and ... allergy, and audiology practice in Westchester County takes the ... technology, a superb underlying corporate structure and protocols, and ... also takes a leading Chief Financial Officer to help ... (WCBJ), that’s exactly what it possesses. In fact, in ...
Breaking Medicine News(10 mins):Health News:Older adults are at risk of financial abuse 2Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3
... BAYFIELD, Colo., July 14 Kanakuk Colorado today released the ... illness. , , "Yesterday, Kanakuk ... that at 2:00 p.m. on Saturday afternoon 2 campers presented to ... throats. Within 30 minutes these campers had been isolated from the ...
... , , , ... an older adult can easily turn into a downward slide into a ... health care for the elderly, Aurora Health Care is sponsoring a continuing ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ) , ...
... BINGHAM FARMS, Mich., July 14 United Physicians ... 1st, 2009. The decision to take a more eco-friendly ... faxes that have historically been used to communicate with the ... "The decision to ,Go Green, with our business communications ...
... HAYWARD, Calif., July 14 Solta Medical, Inc. (Nasdaq: ... today announced that it will release its financial results for the ... Thursday, July 30, 2009. The Company will also host a ... p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results ...
... MIAMI and SAN DIEGO, July 14 Sorrento ... for the generation of fully human monoclonal antibodies, and QuikByte ... no active operations, have signed a merger agreement pursuant to ... QuikByte. After the merger is completed, QuikByte will be ...
... compliance, study finds , TUESDAY, July 14 (HealthDay News) -- ... use of a reminder program for women who were due ... Permanente staff checked electronic health records of its 35,000 members ... a mammogram for 20 months. They were sent a postcard ...
Cached Medicine News:Health News:Statement for Attribution to Andy Braner, President, Kanakuk Colorado, Bayfield CO 2Health News:Aurora Health Care Sponsors Education Event to Improve Care for the Elderly 2Health News:Aurora Health Care Sponsors Education Event to Improve Care for the Elderly 3Health News:Aurora Health Care Sponsors Education Event to Improve Care for the Elderly 4Health News:United Physicians Goes Green Effective August 1st, 2009 2Health News:Solta Medical, Inc. Announces Second Quarter 2009 Results Release Date and Conference Call 2Health News:QuikByte Software, Inc. and Sorrento Therapeutics, Inc. Announce Merger Agreement 2Health News:QuikByte Software, Inc. and Sorrento Therapeutics, Inc. Announce Merger Agreement 3Health News:Reminders Boost Mammography Appointments 2
... bench style refrigerator (can be situated on or ... of bags is to be stored as in ... white colorbond steel while the interior is a ... door is key lockable. Control panel is flush ...
The Testosterone Enzyme Immunoassay is intended for the quantitative determination of Testosterone concentration in human serum. No special pretreatment of the sample is necessary. For in vitro Diag...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... This HPLC for Vitamin B6 makes ... an easy, fast and precise method. The ... form for preparation and separation of the ... of HPLC analytics is the simultaneous handling ...
Medicine Products: